NPM1 mutation

News alerts, weekly reports and conference planners

Entrez ID:

4869

Related biomarkers:

‹

›

NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New C3) gemtuzumab ozogamicin Sensitive : A2 EHA 2023 - 2wk	gemtuzumab ozogamicin Sensitive: A2 - Guideline EHA 2023 - 2 weeks gemtuzumab ozogamicin Sensitive : A2 EHA 2023 - 2 weeks - (New C3)
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: B - Late Trials EHA 2023 - 2 weeks (New C3) venetoclax Sensitive : B EHA 2023 - 2wk	venetoclax Sensitive: B - Late Trials EHA 2023 - 2 weeks venetoclax Sensitive : B EHA 2023 - 2 weeks - (New C3)
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks (New C3) KO-539 Sensitive : C2 EHA 2023 - 2wk	KO-539 Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks KO-539 Sensitive : C2 EHA 2023 - 2 weeks - (New C3)
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine Sensitive: B - Late Trials cytarabine Sensitive : B	cytarabine Sensitive: B - Late Trials cytarabine Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	SNDX-5613 Sensitive: B - Late Trials SNDX-5613 Sensitive : B	SNDX-5613 Sensitive: B - Late Trials SNDX-5613 Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	SNDX-5613 Sensitive: C2 – Inclusion Criteria SNDX-5613 Sensitive : C2	SNDX-5613 Sensitive: C2 – Inclusion Criteria SNDX-5613 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	HAG + azacitidine Sensitive: C2 – Inclusion Criteria HAG + azacitidine Sensitive : C2	HAG + azacitidine Sensitive: C2 – Inclusion Criteria HAG + azacitidine Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine Sensitive: C3 – Early Trials cytarabine Sensitive : C3	cytarabine Sensitive: C3 – Early Trials cytarabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	FLAI Sensitive: C3 – Early Trials FLAI Sensitive : C3	FLAI Sensitive: C3 – Early Trials FLAI Sensitive : C3
NPM1 mutation	Chronic Myelomonocytic Leukemia	NPM1 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
NPM1 mutation	Myelodysplastic Syndrome	NPM1 mutation	Myelodysplastic Syndrome	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3
NPM1 mutation	Myelodysplastic Syndrome	NPM1 mutation	Myelodysplastic Syndrome	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + IACS-010759 Sensitive: D – Preclinical venetoclax + IACS-010759 Sensitive : D	venetoclax + IACS-010759 Sensitive: D – Preclinical venetoclax + IACS-010759 Sensitive : D
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	EPZ004777 Sensitive: D – Preclinical EPZ004777 Sensitive : D	EPZ004777 Sensitive: D – Preclinical EPZ004777 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	NSC348884 Sensitive: D – Preclinical NSC348884 Sensitive : D	NSC348884 Sensitive: D – Preclinical NSC348884 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	DS-1594 Sensitive: D – Preclinical DS-1594 Sensitive : D	DS-1594 Sensitive: D – Preclinical DS-1594 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + KO-539 Sensitive: D – Preclinical venetoclax + KO-539 Sensitive : D	venetoclax + KO-539 Sensitive: D – Preclinical venetoclax + KO-539 Sensitive : D

NPM1 mutation

Associations